Pazopanib in Refractory Solid Tumors

The purpose of this study is to test the safety of pazopanib in children, adolescents and young adults. We want to find out what effects; good or bad, pazopanib has on patients aged from 12 months to 18 years of age, including how much of the drug gets into the blood stream and the lowest amount of drug that remains in your blood stream between doses. We will also look at whether your disease is stable or you have progression of your disease after you stop taking pazopanib. You have been asked to take part in the study because you have one of the following tumors that have come back after treatment or is not responding to your current treatment: • Rhabdomyosarcoma • Non-rhabdomyosarcomatous soft tissue sarcoma • Ewing Sarcoma/ peripheral primitive neuro-ectodermal tumor • Osteosarcoma • Neuroblastoma • Hepatoblastoma The study medication pazopanib is not yet approved for doctors to treat patients who are 18 years old or younger with these types of tumors. Between 77 and 154 patients at approximately 60 clinics or hospitals in the U.S. and Canada will take part in this study.

July 03, 2017